Request for lead compounds for cancer treatments to University of Freiburg(Germany) Preclinical studies for evaluation of efficacy and safety of KML001 by Notox (Netherlands)
Completion of “Clinical phase I study of oral KML001 monotherapy in patients with bone metastatic hormone-refractory prostate cancers not amenable to standard systemic chemotherapy” in Germany
Initiation of “Clinical Phase II Study of KOMINOX (KML001) in Patient with Hormone Refractory Prostate cancer” in Korea.
Start of “Phase I Trial of Cisplatin and KML001 in Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies” by University of Maryland Greenebaum Cancer Center (UMGCC) Supported by National Cancer Institute (NCI, USA) Start of phase I clinical study in patient with solid tumors in Korea Start of phase II clinical studies in Patient with cholangiocarcinoma, HCC and NHL
Start of “Phase II Study to Assess the Clinical Benefit of 3 Doses of PAX-1 as Adjunctive Treatment for Persistent Cancer Pain” in 10 Australian Hospitals including flinders university repatriation general hospital
Completion of Kominox factory establishment in preparing for phase III clinical trials and launching (cost of construction: \ 40 billion)
